Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Education
  • General

If You Invested $1,000 In Coca-Cola Stock When Vitaminwater Was Acquired, Here’s How Much You’d Have Now

By Chris Katje
July 28, 12:05 PM
Beverage giant The Coca-Cola Company (NYSE: KO) has not shied away from acquiring other smaller beverage brands to expand its portfolio. Here’s a look at how one acquisition paid off for the company and its shareholders.

KO

Read More
1 minute read
  • General
  • News
  • Politics

President Biden Told Xi U.S. Doesn’t Back Taiwan Independence

By Benzinga Newsdesk
July 28, 12:05 PM
-Reuters

FXI

Read More
1 minute read
  • General
  • News
  • Politics

President Biden Tweets ‘After historic economic growth – regaining all private sector jobs lost during the pandemic – we knew the economy would slow down as the Fed acts on inflation.’

By Benzinga Newsdesk
July 28, 11:51 AM
https://twitter.com/POTUS/status/1552682795968987139

SPY

Read More
3 minute read
  • Biotech
  • Earnings
  • FDA
  • Financing
  • General
  • Health Care
  • IPOs
  • Large Cap
  • Legal
  • News
  • Penny Stocks
  • Small Cap

Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate

By Vandana Singh
July 28, 10:37 AM
Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • News

Hershey Sweetens FY22 Forecast On Q2 Earnings Beat

By Shivani Kumaresan
July 28, 9:59 AM
Hershey Co (NYSE:HSY) reported second-quarter FY22 sales growth of 19.3% year-on-year, to $2.37 billion, beating the consensus of $2.22 billion. Hershey’s…

HSY

Read More
1 minute read
  • General
  • News
  • Politics

President Biden Says It’s No Surprise That The Economy Is Slowing Down As The Federal Reserve Acts To Bring Down Inflation; Says We Are On The Right Path; Job Market Historically Strong And Consumer Spending Continues To Grow

By Benzinga Newsdesk
July 28, 9:45 AM
-Reuters

SPY

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • News

Marlboro Maker Altria Reaffirms FY22 Earnings Guidance Post Q2 Beat

By Shivani Kumaresan
July 28, 9:37 AM
Marlboro maker Altria Group Inc (NYSE:MO) reported a second-quarter FY22 sales decline of 5.7% year-on-year, to $6.54 billion, beating the consensus of…

MO

Read More
4 minute read
  • Biotech
  • General
  • Health Care
  • News

AIM ImmunoTech Reports Positive Pilot Study Data From Expanded Access Program Evaluating Ampligen For The Treatment Of Long COVID-19

By Michael Horton
July 28, 9:11 AM
AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Atossa Therapeutics Announces Dosing Completed In Part C of Atossa’s Phase 1/2a Study Of AT-H201 In Healthy Volunteers

By Benzinga Newsdesk
July 28, 9:05 AM
Atossa Therapeutics, Inc. (NASDAQ:ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current

ATOS

Read More
3 minute read
  • Biotech
  • General
  • News

Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

By Michael Horton
July 28, 8:55 AM
Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a

CYTO

Posts pagination

Previous 1 … 2,285 2,286 2,287 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service